Aadi Bioscience (NASDAQ:AADI) Shares Down 1.4% - Here's Why

Key Points

• Shares fell 1.4% intraday to $4.15 (low $4.13) on volume of 147,172 shares, a 44% decline from the average session volume.
• Clinical-stage biotech with a market cap of about $102.5M and a negative P/E (-1.82), Aadi is developing precision oncology drugs, led by fimepinostat (CUDC-907), a dual HDAC/PI3K inhibitor for genomically defined cancers.

Aadi Bioscience, Inc. (NASDAQ:AADI - Get Free Report) traded down 1.4% during mid-day trading on Thursday . The stock traded as low as $4.13 and last traded at $4.15. 147,172 shares traded hands during trading, a decline of 44% from the average session volume of 261,100 shares. The stock had previously closed at $4.21.

Aadi Bioscience Trading Down 1.4%

The firm has a market capitalization of $102.49 million, a price-to-earnings ratio of -1.82 and a beta of 0.68. The company's 50 day moving average is $3.69 and its 200-day moving average is $2.93.

About Aadi Bioscience

Aadi Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genomically defined cancers. Headquartered in Redwood City, California, Aadi Bioscience was founded in 2012 and went public in 2019 on the Nasdaq Stock Market under the ticker AADI. The company's research strategy centers on identifying molecular drivers of tumor growth and designing small-molecule inhibitors that target these pathways.

The company's lead product candidate, fimepinostat (CUDC-907), is a novel dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.